New tech can predict heart attack risk
Washington: A new imaging technology may help predict who is at risk of heart attack, scientists claim.
Researchers with Spectrum Health`s Frederik Meijer Heart & Vascular Instituten in US used the technology on patients being treated for heart attacks.
The imaging technology allowed researchers to identify the characteristic makeup, or signature, of arterial plaque blocking an artery and causing a heart attack.
Knowing what type of plaque is present in narrowed arteries may help a physician determine a patient`s risk for heart attacks and may lead to novel treatment options to avoid a serious cardiac event.
Previous research during autopsies has shown that most major heart attacks called ST-segment elevation myocardial infarctions (STEMIs) are caused by the rupture of lipid core plaque (LCP), a type of plaque rich in cholesterol.
However, this is the first study to document the presence of LCP in living patients. The LCP was detected with the use of near-infrared spectroscopy (NIRS) performed with a special coronary catheter.
The study used this NIRS system to measure cholesterol in the plaques of 20 patients experiencing a STEMI. The measurements were made after blood flow was reestablished but before a stent was placed to keep the artery open.
"We have discovered a NIRS signature of the plaques which caused myocardial infarction, a leading cause of death and injury worldwide," said Ryan Madder, a Spectrum Health interventional cardiologist and principal investigator of the study.
"This signature is detectable at the time of cardiac catheterisation using a novel intracoronary imaging device. It is our hope that this signature may be capable of predicting a myocardial infarction before it happens," Madder said.
Madder said that these findings provide support for further research of arteries narrowed with LCP. He`s interested in conducting a prediction study to determine if patients with significant deposits of LCP do have a higher risk of heart attack.
The imaging system was developed by Infaredx, Inc, and uses advanced plaque characterisation technology, NIRS, with intravascular ultrasound, for identification of plaque structure.
The findings will appear in JACC: Cardiovascular Interventions, published by the American College of Cardiology.